Drug Price Trends for NDC 75834-0148

Average Pharmacy Cost for 75834-0148

Drug Name	NDC	Price/Unit ($)	Unit	Date
FLUOXETINE HCL 60 MG TABLET	75834-0148-30	0.44825	EACH	2025-03-19
FLUOXETINE HCL 60 MG TABLET	75834-0148-30	0.40398	EACH	2025-02-19
FLUOXETINE HCL 60 MG TABLET	75834-0148-30	0.34983	EACH	2025-01-22

Best Wholesale Price for NDC 75834-0148

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
No data available in table

Market Analysis and Price Projections for NDC 75834-0148: Fluoxetine by Nivagen Pharmaceuticals

The pharmaceutical industry is a complex and ever-evolving landscape, with drug prices and market trends constantly shifting. In this comprehensive analysis, we'll delve into the market dynamics and price projections for the drug identified by National Drug Code (NDC) 75834-0148, which is Fluoxetine manufactured by Nivagen Pharmaceuticals, Inc.

Understanding NDC 75834-0148

Before we dive into the market analysis, it's crucial to understand what NDC 75834-0148 represents. The National Drug Code is a unique, three-segment number assigned by the U.S. Food and Drug Administration (FDA) to human drugs in the United States[4]. For NDC 75834-0148:

• 75834 is the labeler code, identifying Nivagen Pharmaceuticals, Inc.
• 0148 is the product code, specific to Fluoxetine and its formulation
• The package code is not provided in this NDC, but it would identify the specific package size and type

Fluoxetine, commonly known by its brand name Prozac, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It's used to treat conditions such as major depressive disorder, obsessive-compulsive disorder, and panic disorder.

Current Market Position of Fluoxetine

Fluoxetine has been a staple in the antidepressant market since its introduction in the 1980s. As a generic drug, it faces competition from other manufacturers, which typically leads to price erosion over time. However, the demand for antidepressants has been steadily increasing, particularly in light of global events such as the COVID-19 pandemic.

Market Share and Competition

While specific market share data for Nivagen's Fluoxetine is not provided in the search results, we can infer some information based on industry trends:

• Generic drugs, including Fluoxetine, are expected to experience mid-single-digit percent annual price erosion[3].
• The overall generic drug industry is anticipated to see modest revenue growth, despite price pressures[3].

Factors Influencing Price Projections

Several factors will influence the price projections for NDC 75834-0148:

1. Generic Drug Market Trends

The generic drug industry is facing challenges that could impact pricing:

• Mid-single-digit percent annual price erosion is expected[3].
• Price-fixing litigation and increased FDA inspections of foreign manufacturing facilities pose risks to the industry[3].

2. Overall Pharmaceutical Market Outlook

Vizient projects drug price inflation to grow at 3.8% in the latest Pharmacy Market Outlook. Driven in part by specialty pharmacy, including the increasing utilization of weight loss drugs, it is the highest projected increase since July 2019.[2]

This overall inflation trend may indirectly affect generic drug pricing, as healthcare providers and payers seek to balance their budgets.

3. Regulatory Environment

The FDA's actions, including increased inspections and potential policy changes, can significantly impact drug pricing. For generic manufacturers like Nivagen, compliance with regulatory requirements is crucial and can affect production costs.

4. Supply Chain Dynamics

Global supply chain issues, which have been exacerbated by recent world events, can influence the cost of raw materials and manufacturing, potentially impacting the final price of Fluoxetine.

5. Demand for Mental Health Medications

The ongoing global focus on mental health, particularly in the wake of the COVID-19 pandemic, may sustain or increase demand for antidepressants like Fluoxetine.

Price Projection Scenarios

Given the available information, we can outline several potential scenarios for the pricing of NDC 75834-0148 over the next 18-24 months:

Scenario 1: Moderate Price Erosion

In this scenario, Fluoxetine (NDC 75834-0148) follows the general trend of generic drugs:

• Annual price erosion of 3-5%
• Slight decrease in profit margins for Nivagen Pharmaceuticals
• Maintained market share due to consistent demand

Scenario 2: Stabilized Pricing

Factors that could lead to price stabilization include:

• Increased demand offsetting downward price pressures
• Supply chain optimizations reducing production costs
• Strategic pricing to maintain market position

Scenario 3: Slight Price Increase

While less likely for a generic drug, a slight price increase could occur due to:

• Overall drug price inflation trends (projected 3.8% by Vizient)[2]
• Increased production costs passed on to consumers
• Potential supply shortages or manufacturing challenges

Market Strategies for Nivagen Pharmaceuticals

To navigate the evolving market landscape, Nivagen Pharmaceuticals might consider the following strategies:

1. Cost Optimization

Implementing efficient manufacturing processes and supply chain management to reduce production costs without compromising quality.

2. Portfolio Diversification

Expanding their product range to include other high-demand generic medications or exploring specialty pharmacy options.

3. Strategic Partnerships

Collaborating with healthcare providers and payers to secure long-term contracts and stable pricing agreements.

4. Innovation in Formulation

Investing in research to develop improved formulations or delivery methods for Fluoxetine, potentially justifying premium pricing.

5. Market Expansion

Exploring new geographical markets or distribution channels to increase sales volume and offset potential price erosion.

Long-term Outlook for Fluoxetine Market

Looking beyond the immediate future, several factors could shape the long-term market for Fluoxetine:

Advancements in Mental Health Treatment

Ongoing research into depression and related disorders could lead to new treatment modalities, potentially impacting the demand for traditional SSRIs like Fluoxetine.

Personalized Medicine Trends

The move towards personalized medicine may influence prescribing patterns, potentially segmenting the antidepressant market further.

Regulatory Changes

Potential changes in healthcare policy or drug pricing regulations could significantly affect the generic drug market, including Fluoxetine.

Global Mental Health Initiatives

Increased global focus on mental health could expand markets for antidepressants, particularly in developing countries.

Comparative Analysis with Other Antidepressants

To better understand Fluoxetine's market position, it's helpful to compare it with other antidepressants:

SSRIs

• Sertraline (Zoloft)
• Escitalopram (Lexapro)
• Paroxetine (Paxil)

SNRIs

• Venlafaxine (Effexor)
• Duloxetine (Cymbalta)

While specific pricing data for these drugs is not provided in the search results, the generic versions of these medications likely face similar market pressures as Fluoxetine.

Impact of Emerging Therapies

The antidepressant market is not static, and emerging therapies could influence Fluoxetine's market share and pricing:

Ketamine and Esketamine

These rapid-acting antidepressants have gained attention for treatment-resistant depression, potentially affecting the market for traditional SSRIs.

Digital Therapeutics

FDA-approved digital treatments for depression could complement or compete with pharmacological interventions.

Psychedelic-Assisted Therapies

Ongoing research into psychedelic compounds for mental health treatment may reshape the antidepressant landscape in the long term.

Challenges and Opportunities for Generic Manufacturers

Generic drug manufacturers like Nivagen Pharmaceuticals face unique challenges and opportunities in the current market:

Challenges

1. Price erosion due to competition
2. Regulatory compliance costs
3. Supply chain vulnerabilities
4. Brand loyalty to originator drugs

Opportunities

1. Expanding markets in developing countries
2. Increased focus on cost-effective healthcare solutions
3. Potential for authorized generic partnerships with brand-name manufacturers
4. Innovation in drug delivery systems

Key Takeaways

• NDC 75834-0148 represents Fluoxetine manufactured by Nivagen Pharmaceuticals, Inc.
• The generic drug market is expected to face mid-single-digit percent annual price erosion.
• Overall drug price inflation is projected at 3.8%, driven by specialty pharmaceuticals.
• Fluoxetine's pricing may follow moderate erosion, stabilization, or slight increase scenarios.
• Long-term market outlook depends on advancements in mental health treatment, personalized medicine trends, and regulatory changes.
• Emerging therapies and digital solutions may impact the traditional antidepressant market.
• Generic manufacturers face challenges in price competition but have opportunities in expanding markets and innovation.

FAQs

1. Q: How does the NDC system work for identifying drugs like Fluoxetine? A: The National Drug Code (NDC) is a unique, three-segment number assigned by the FDA. For Fluoxetine (NDC 75834-0148), 75834 identifies Nivagen Pharmaceuticals, 0148 specifies the product formulation, and the package code (not provided) would indicate the package size and type.

2. Q: What factors are most likely to influence Fluoxetine pricing in the next 18-24 months? A: Key factors include generic drug market trends, overall pharmaceutical price inflation, regulatory changes, supply chain dynamics, and demand for mental health medications.

3. Q: How might emerging therapies impact the market for traditional antidepressants like Fluoxetine? A: Emerging therapies such as ketamine-based treatments, digital therapeutics, and psychedelic-assisted therapies could potentially reshape the antidepressant market, affecting demand and pricing for traditional SSRIs like Fluoxetine.

4. Q: What strategies can generic manufacturers like Nivagen Pharmaceuticals employ to remain competitive? A: Strategies include cost optimization, portfolio diversification, strategic partnerships, innovation in formulation, and market expansion into new geographical areas or distribution channels.

5. Q: How might global mental health initiatives affect the long-term outlook for Fluoxetine? A: Increased global focus on mental health could potentially expand markets for antidepressants like Fluoxetine, particularly in developing countries, potentially offsetting price erosion in established markets.

Sources cited: [1] https://www.findacode.com/ndc/labelers/Nivagen_Pharmaceuticals,_Inc.--75834 [2] https://www.vizientinc.com/newsroom/news-releases/2024/vizient-projects-3-8-drug-price-increase-driven-by-specialty-pharmaceuticals [3] https://www.drugpatentwatch.com/p/drug-price/ndc/69315-0275 [4] https://www.fda.gov/drugs/development-approval-process-drugs/national-drug-code-database-background-information